Teva Pharmaceuticals Shares Rise After FDA Approves Weltruza for Schizophrenia
By Chris Wack
Teva Pharmaceuticals Industries shares rose after the company's Teva Pharmaceutical affiliate said the Food and Drug Administration has approved Weltruza for extended-release injectable suspension for the treatment of schizophrenia in adults.
The stock was 6% higher, at $41.56, in morning trade, after hitting its 52-week high of $41.69 just after the market opened.
The company said Weltruza clinical trial results demonstrated improvement in symptoms and significant reduction in illness severity, as well as improvement in personal and social functioning.
Teva said that in the coming weeks, Weltruza will be available in three different strengths - 318 mg, 425 mg and 531 mg - with no loading doses, no oral supplementation and no post-injection monitoring required.
In a phase 3 trial, all three doses of Weltruza were similarly tolerated, with the most common reported adverse events inclusive of increased weight, somnolence, headache, constipation and injection site reactions.
Teva said Weltruza will be available in the U.S. in the coming weeks.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 09, 2026 10:21 ET (14:21 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
Christine Benz: Why I Hired a Financial Planner
United States